IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 222 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2263    
    Printed78    
    Emailed0    
    PDF Downloaded88    
    Comments [Add]    

Recommend this journal

 

 SYSTEMATIC REVIEW
Year : 2021  |  Volume : 53  |  Issue : 4  |  Page : 317-327

Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review


1 Department of Ophthalmology, Government Medical College and Hospital, Bathinda, Punjab, India
2 Department of Pharmacology, PGIMER, Bathinda, Punjab, India
3 Department of Internal Medicine, Silchar Medical College and Hospital, Assam, India
4 Department of Anaesthesia, Assam Medical College and Hospital, Assam, India
5 Biophysics, PGIMER, Bathinda, Punjab, India
6 Scientific Officer, Department of Pharmacology, Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh, India
7 Department of Pharmacology, Central University of Punjab, Bathinda, Punjab, India
8 Department of Microbiology, Assam Medical College and Hospital, Assam, India

Correspondence Address:
Prof. Bikash Medhi
Department of Pharmacology, PGIMER, Chandigarh - 160 012
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijp.ijp_419_21

Rights and Permissions

Since the onset of COVID-19 pandemic, parallel opportunistic infections have also been emerging as another disease spectrum. Among all these opportunistic infection, mucormycosis has become a matter of concern with its rapid increase of cases with rapid spread as compared to pre-COVID-19 era. Cases have been reported in post-COVID-19-related immune suppression along with the presence of comorbidity which adds on the deadly outcome. There is no systematic review addressing the issue of COVID-19-associated mucormycosis. This is the first systematic review of published studies of mucormycosis associated with COVID-19. The aim was to analyze the real scenario of the disease statement including all the published studies from first November 2019 to 30th June to analyze the contemporary epidemiology, clinical manifestations, risk factor, prognosis, and treatment outcome of COVID-19 associated rhino-orbito-cerebral-mucormycosis. A comprehensive literature search was done in following databases, namely, PubMed, Google Scholar, Scopus, and EMBASE using keywords mucormycosis, rhino orbital cerebral mucormycosis, COVID-19, and SARS-CoV-2 (from November 01, 2019 to June 30, 2021). Our study shows that, while corticosteroids have proved to be lifesaving in severe to critical COVID-19 patients, its indiscriminate use has come with its price of rhino-orbito-cerebral mucormycosis epidemic, especially in India especially in patients with preexisting diabetes mellitus with higher mortality. Corticosteroid use should be monitored and all COVID-19 patients should be closely evaluated/monitored for sequelae of immunosuppression following treatment.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow